Cationic Diclofenac Lipid Nanoemulsion for Improved Oral Bioavailability : Preparation , Characterization and In Vivo Evaluation

Cationic nanoemulsions were reported to have increased bioavailability. The aim of present study was to prepare a cationic lipid nanoemulsion of diclofenac acid (LNEs) for improved oral bioavailability to treat arthritic conditions. The LNEs of diclofenac acid were prepared by using soya bean oil, egg lecithin, cholesterol and stearylamine. Stearylamine was used as positive charge inducer. The LNEs were processed by homogenization and ultrasonication. The formulation composition was selected based on earlier reports. The LNEs were characterized for size and zeta potential. The physical stability of LNEs was studied using autoclaving, centrifugal, desorption (dilution effect) stresses and on storage. The total drug content and entrapment efficiency were determined using HPLC. During in vivo studies in Wistar rats, the pharmacokinetic parameters of LNEs were compared with a prepared diclofenac suspension in sodium CMC mucilage. The selected formulations, F1, F2 and F3, were relatively stable during centrifugal stress, dilution stress and on storage. The drug content was found to be 2.38 ± 1.70 mg/ml for F1, 2.30 ± 0.82 mg/ml for F2, and 2.45 ± 0.66 mg/ml for F3. The entrapment efficiencies were 97.83 ± 0.53%, 97.87 ± 1.22% and 98.25 ± 0.21% for F1, F2 and F3 respectively. The cumulative percentage drug release from F1, F2 and F3 showed more release in pH 6.8 phosphate buffer than in pH 1.2 HCl. During oral bioavailability studies, the LNEs showed higher serum concentrations than a suspension. The relative bioavailability of the LNE formulations F1, F2 and F3 were found to be 2.35, 2.94 and 6.28 times that of F4 suspension and were statistically significant. Of all, the cationic lipid nanoemulsion (F3) was superior in improving bioavailability, when compared with plain emulsion (F1) and cholesterol containing LNE (F2). The study helps in designing the cationic oral nanoemulsions to improve the oral bioavailability of diclofenac.

[1]  Prabhakar Kandadi,et al.  Albumin coupled lipid nanoemulsions of diclofenac for targeted delivery to inflammation. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[2]  F. Behar-Cohen,et al.  Ocular antisense oligonucleotide delivery by cationic nanoemulsion for improved treatment of ocular neovascularization: an in-vivo study in rats and mice. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[3]  F. Lallemand,et al.  Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb , 2012, Journal of drug delivery.

[4]  F. Behar-Cohen,et al.  Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[5]  G. Triadafilopoulos,et al.  Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. , 2006, The American journal of medicine.

[6]  Malcolm J. W. Povey,et al.  A comparative study of ultrasound and laser light diffraction techniques for particle size determination in dairy beverages , 2006 .

[7]  F. Jamali,et al.  A comparison of gastrointestinal permeability induced by diclofenac-phospholipid complex with diclofenac acid and its sodium salt. , 2003, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[8]  G. Wood,et al.  Improving emulsification efficacy of lecithin by formulation design. I: Effect of adding a secondary surfactant. , 1998, PDA journal of pharmaceutical science and technology.

[9]  B. Lundberg.  A Submicron Lipid Emulsion Coated with Amphipathic Polyethylene Glycol for Parenteral Administration of Paclitaxel (Taxol) , 1997, The Journal of pharmacy and pharmacology.

[10]  T. Redgrave,et al.  Submicron lipid emulsions containing amphipathic polyethylene glycol for use as drug-carriers with prolonged circulation time , 1996 .

[11]  P. Fowler,et al.  Diclofenac (Voltarol) in rheumatoid arthritis: a report of a double-blind trial. , 1978, Rheumatology and rehabilitation.

[12]  Prabhakar Kandadi,et al.  Formulation and Pharmacokinetics of Diclofenac Lipid Nanoemulsions for Parenteral Application , 2012, PDA Journal of Pharmaceutical Science and Technology.

[13]  P. G. Welling,et al.  The pharmacokinetics of diclofenac sodium following intravenous and oral administration , 2004, European Journal of Clinical Pharmacology.

[14]  S. Benita,et al.  Positively charged self-emulsifying oil formulation for improving oral bioavailability of progesterone. , 1996, Pharmaceutical development and technology.

[15]  M. Kurowski.  [Pharmacokinetics and biological availability of diclofenac preparations following intramuscular injection of 75 mg and oral administration of 150 mg of active drug]. , 1988, Zeitschrift fur Rheumatologie.

[16]  R. Sane,et al.  High Performance Liquid Chromatographic Determination of Diclofenac Sodium from Pharmaceutical Preparation , 1987 .

[17]  M. Kendall,et al.  Factors affecting the pharmacokinetics of diclofenac sodium (Voltarol). , 1979, Rheumatology and rehabilitation.

[18]  A. Sallmann,et al.  Pharmacological properties of diclofenac sodium and its metabolites. , 1978, Scandinavian journal of rheumatology. Supplement.